
### [NCIT:C6570](http://purl.obolibrary.org/obo/NCIT_C6570)
**Label:** Extraskeletal Cartilaginous and Osseous Neoplasm

**Subclasses:** [NCIT:C6615](http://purl.obolibrary.org/obo/NCIT_C6615) (Mediastinal Extraskeletal Osteosarcoma), [NCIT:C5833](http://purl.obolibrary.org/obo/NCIT_C5833) (Liver Extraskeletal Osteosarcoma), [NCIT:C27376](http://purl.obolibrary.org/obo/NCIT_C27376) (Childhood Extraskeletal Osteosarcoma), [NCIT:C7925](http://purl.obolibrary.org/obo/NCIT_C7925) (Adult Extraskeletal Osteosarcoma), [NCIT:C8810](http://purl.obolibrary.org/obo/NCIT_C8810) (Extraskeletal Osteosarcoma), [NCIT:C8811](http://purl.obolibrary.org/obo/NCIT_C8811) (Recurrent Extraskeletal Osteosarcoma), [NCIT:C6596](http://purl.obolibrary.org/obo/NCIT_C6596) (Mediastinal Chondroma), [NCIT:C82972](http://purl.obolibrary.org/obo/NCIT_C82972) (Duodenal Extraskeletal Osteosarcoma), [NCIT:C7002](http://purl.obolibrary.org/obo/NCIT_C7002) (Central Nervous System Extraskeletal Osteosarcoma), [NCIT:C5189](http://purl.obolibrary.org/obo/NCIT_C5189) (Breast Extraskeletal Osteosarcoma), [NCIT:C6572](http://purl.obolibrary.org/obo/NCIT_C6572) (Malignant Extraskeletal Cartilaginous and Osseous Neoplasm), [NCIT:C7001](http://purl.obolibrary.org/obo/NCIT_C7001) (Central Nervous System Chondroma), [NCIT:C6571](http://purl.obolibrary.org/obo/NCIT_C6571) (Benign Extraskeletal Cartilaginous and Osseous Neoplasm), [NCIT:C6181](http://purl.obolibrary.org/obo/NCIT_C6181) (Kidney Extraskeletal Osteosarcoma), [NCIT:C9482](http://purl.obolibrary.org/obo/NCIT_C9482) (Soft Tissue Chondroma), [NCIT:C45629](http://purl.obolibrary.org/obo/NCIT_C45629) (Lung Chondroma), [NCIT:C8808](http://purl.obolibrary.org/obo/NCIT_C8808) (Metastatic Extraskeletal Osteosarcoma), 

**Class expressions from DL-Learner:**

- [NCIT:C36985](http://purl.obolibrary.org/obo/NCIT_C36985) (Neoplastic Chondroblast) 53.33%
- [NCIT:C27962](http://purl.obolibrary.org/obo/NCIT_C27962) (Radiation Toxicity) 53.33%
- Thing 53.15%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39959](http://purl.obolibrary.org/obo/NCIT_C39959) (Mixed Squamous Cell Carcinoma of the Penis))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39957](http://purl.obolibrary.org/obo/NCIT_C39957) (Epididymal Adenocarcinoma))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39956](http://purl.obolibrary.org/obo/NCIT_C39956) (Rete Testis Adenoma))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C3994](http://purl.obolibrary.org/obo/NCIT_C3994) (Stage IV Colon Cancer AJCC v6))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C3993](http://purl.obolibrary.org/obo/NCIT_C3993) (Stage II Colon Cancer AJCC v6))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39914](http://purl.obolibrary.org/obo/NCIT_C39914) (Gain of Chromosome 12p))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 38.69%
- [NCIT:C48898](http://purl.obolibrary.org/obo/NCIT_C48898) (Painless Mass) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 38.69%


